California researchers target immunotherapy for melanoma

March 2013
Medical Device Daily;3/27/2013, Vol. 17 Issue 59, Special section p1
This article reports on an immunotherapy approach developed by scientists at the University of California Los Angeles and the California Institute of Technology to combat melanoma.


Related Articles

  • EYEING BRAF inhibitors. Gagnon, Louise // Dermatology Times;Jul2013, Vol. 34 Issue 7, p40 

    The article discusses the developments in using BRAF inhibitors for the treatment of metastatic melanoma as of 2013. Doctor Igor Puzanov of Vanderbilt University Medical Center in Nashville, Tennessee stated that about 50% of melanoma carry mutations of the BRAF oncogene. Immunotherapy and...

  • New treatments are improving outcomes in melanoma. Schieszer, John // Oncology Nurse Advisor;Sep/Oct2011, Vol. 2 Issue 5, p22 

    No abstract available.

  • Nanotechnology Leads to New Treatments. Klotter, Jule // Townsend Letter;Aug/Sep2009, Issue 313/314, p32 

    The article focuses on nanomedicine, a branch of nanotechnology, which is said to lead to new cancer drug delivery methods and treatments. Nanoliposomes, which are hollow spheres of fatty acids, filled with a drug aimed at mutated genes characteristics of melanoma were engineered by researchers...

  • Immunotherapy for the Management of Advanced Melanoma: The Next Steps. Zikich, Dragoslav; Schachter, Jacob; Besser, Michal // American Journal of Clinical Dermatology;2013, Vol. 14 Issue 4, p261 

    Melanoma is an immunogenic tumor that can induce a natural immune response. A number of immunotherapy-based approaches have been developed over the past decades, and certain degrees of effectiveness were achieved by the use of cytokines, adoptive cell transfer and T-cell immune modulators....

  • The tumor biology of melanoma nodal metastases. Miliotes, Gregory; Albertini, John // American Surgeon;Jan1996, Vol. 62 Issue 1, p81 

    Discusses the study on patients with melanoma and how they fared during treatment. Information on operative surgical approach; Research methodology; Results of research; Discussion of findings; Reference material.

  • All-cause mortality may add bias to survival studies. Yaghouti, Farzad // Ophthalmology Times;01/15/98, Vol. 23 Issue 2, p12 

    Highlights the results of a study conducted by ophthalmologist Devron H. Char and colleagues on the mortality of patients who undergo radiation for uveal melanoma. Overall mortality in patients with irradiated melanomas; Definition of tumor-related mortality; Prognostic factors for either...

  • Multiple melanomas can be cured.  // USA Today Magazine;Oct96, Vol. 125 Issue 2617, p6 

    Reports that multiple primary melanomas do not necessarily imply a poorer diagnosis. Need for realization that melanoma is treatable and that a cure is immanent; Importance of early detection.

  • Advanced malignant melanoma needs effective Tx. Guttman, Cheryl // Dermatology Times;Oct96, Vol. 17 Issue 10, p4 

    Discusses the need for more research on therapies for advanced malignant melanoma. Experiments on adjuvant radiotherapy following head and neck lymph node dissection; Clinical trials of vaccines; Treatment with interferon alfa-2b.

  • In the labs: Maxim Pharmaceuticals Inc. Acello, Richard // San Diego Business Journal;07/21/97, Vol. 18 Issue 29, p16 

    Presents information on the development of advanced malignant melanoma treatments at Maxim Pharmaceutical Incorporated. Who will take part in the trial of the treatment; Other developments on the treatment; Comments on the treatment.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics